baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

JP Morgan Put 160 BIIB 16.01.2026/ DE000JT60L02 /

07/10/2024 09:42:49	Chg.0.00	Bid22:00:29	Ask22:00:29	Underlying	Strike price	Expiration date	Option type
1.51EUR	0.00%	- Bid Size: -	- Ask Size: -	Biogen Inc	160.00 USD	16/01/2026	Put

GlobeNewswire 01/09 SAGE INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Invest...

GlobeNewswire 29/08 SAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investo...

GlobeNewswire 26/08 Long Term Investor News: Biogen, Seritage Growth, Arbor Realty, and Five Below Investors are Encoura...

GlobeNewswire 26/08 MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...

GlobeNewswire 22/08 Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...

GlobeNewswire 19/08 Tiziana Life Sciences Appoints New Chief Executive Officer

GlobeNewswire 19/08 Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief ...

GlobeNewswire 15/08 Soleno Therapeutics Announces Updates to its Board of Directors

GlobeNewswire 15/08 Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...

GlobeNewswire 08/08 Royalty Pharma Reports Second Quarter 2024 Results

GlobeNewswire 01/08 C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

TeleTrader 01/08 Biogen books $2.5 billion in Q2 revenue

GlobeNewswire 01/08 Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire 31/07 Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease

GlobeNewswire 30/07 New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecane...

GlobeNewswire 30/07 Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fun...

GlobeNewswire 30/07 Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Path...

GlobeNewswire 26/07 CVS Health Corporation Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law...

GlobeNewswire 26/07 Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

GlobeNewswire 26/07 BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockh...

GlobeNewswire 22/07 Lost Money on Biogen Inc.(BIIB)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Fir...

GlobeNewswire 22/07 DEADLINE ALERT for CMBM, BIIB, DRCT, and FSLY: The Law Offices of Frank R. Cruz Reminds Investors of...

GlobeNewswire 20/07 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Biogen...

GlobeNewswire 20/07 BIIB DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Biogen Inc. (BIIB) Se...

GlobeNewswire 19/07 MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors wit...

JP Morgan Put 160 BIIB 16.01.2026/ DE000JT60L02 /

If you wish to receive reply to your feedback, please provide your email address.